Ankylosing spondylitis management: a narrative review of radiofrequency ablation and naproxen
- 11 June 2025
- journal article
- review article
- Published by Taylor & Francis in Pain Management
- Vol. 15 (8) , 519-526
Abstract
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and reduced mobility. Its pathophysiology remains unclear, complicating treatment development. Management aims to alleviate symptoms and control inflammation, but targeted strategies are lacking. This study compared the efficacy of radiofrequency ablation (RFA) and naproxen in axSpA treatment. A PubMed search was conducted on 14 March 2023 and 27 May 2025. RFA is a minimally invasive procedure that targets nerve endings to block pain signals, while naproxen is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation. We conducted a narrative review of axSpA patients treated with either RFA or naproxen, assessing pain relief, functional improvement, and quality of life. Results showed that RFA was significantly more effective than naproxen in managing chronic pain. Patients receiving RFA reported greater pain reduction and better functional outcomes compared to those on naproxen. RFA provided prolonged relief, while naproxen's effectiveness diminished over time, limiting its long-term benefit. These findings suggest that RFA should be considered a preferred treatment for axSpA patients seeking long-term pain relief and improved quality of life. This study supports RFA's role in managing inflammatory spinal conditions and informs optimal axSpA treatment strategies.Keywords
This publication has 48 references indexed in Scilit:
- Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record dataThe Lancet Regional Health - Europe, 2022
- Radiofrequency ablation and thyroid nodules: updated systematic reviewEndocrine, 2021
- The Pathogenesis of Ankylosing Spondylitis: an UpdateCurrent Rheumatology Reports, 2019
- Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: A 12-week randomized, placebo-controlled, phase I/II clinical trialInternational Immunopharmacology, 2018
- Update on Ankylosing Spondylitis: Current Concepts in PathogenesisCurrent Allergy and Asthma Reports, 2014
- Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trialRheumatology International, 2014
- Feasibility and Safety of Same-Day Home Discharge After Radiofrequency Catheter AblationThe American Journal of Cardiology, 2009
- Pathophysiology of ankylosing spondylitis: What's new?Joint Bone Spine, 2008
- Pulsed radiofrequency for chronic painCurrent Pain and Headache Reports, 2008
- Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: Development of recommendations for clinical practice based on published evidence and expert opinionJoint Bone Spine, 2007